Mirtazapine oral single dose kinetics in patients with different degrees of renal failure

Human Psychopharmacology

Volumn 13, Issue 5, 1998, Pages 357-365

  Bengtsson, F ^a   Hoglund P ^a   Timmer, C ^b   Hegbrant, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NV Organon   (Netherlands)

Author keywords

Antidepressant drugs; Mirtazapine; Pharmacokinetics; Renal failure; Therapeutic drug monitoring (TDM)

Indexed keywords

MIRTAZAPINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG SAFETY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; KIDNEY FAILURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOMNOLENCE;

EID: 0031874360     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199807)13:5<357::AID-HUP8>3.0.CO;2-K     Document Type: Article

References (29)

1. Aronoff, G. R., Bergstrom, R. F., Pottratz, S. T., Sloan, R. S., Wolen, R. L. and Lemberger, L. (1984). Fluoxetine kinetics and protein binding in normal and impaired renal function. Clinical Pharmacology and Therapeutics, 36, 138-144.
2. Bergstrom, R. F., Beasley, C. M. Jr., Levy, N. B., Blumenfield, M. and Lemberger, L. (1991). Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely impaired renal function. Pharmaceutical Research, 8, S294.
3. Bergstrom, R. F., Beasley, C. M. Jr., Levy, N. B., Blumenfield, M. and Lemberger, L. (1993). The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. International Clinical Psychopharmacology, 8, 261-266.
4. de Boer, T., Ruigt, G. S. F. and Berendsen, H. H. G. (1995). The apha2-selective adrenoceptor anatagonist Org 3770 (Mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology, 10, S107-S118.
5. Davis, R. and Wilde, M. I. (1996). Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs, 5, 389-402.
6. Dawling, S., Lynn, K., Rosser, R. and Braithwaite, R. (1982). Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clinical Pharmacology and Therapeutics, 32, 322-329.
7. Delbressine, L. P. C. and Vos, R. M. E. (1997). The clinical relevance of preclinical data: mirtazapine, a model compound. Journal of Clinical Psychopharmacology, 17, 29S-34S.
8. Dengen, J., Wolke, E., Seiberling, M., Pintar, P., Hoxer, G., Steinhauer, H. B. and Fischer, W. (1993). Vergleichende Untersuchung zur Pharmakokinetik von Amitrptylmoxid und Trimipramin nach Einmalgabe bei gesunden manlichen Probanden und Patienten mit Niereninsuffizienz. Mediziniche Klinik, 88, 129-133.
9. Doweiko, J., Fogel, B. S. and Goldberg, R. J. (1984). Trazodone and hemodialysis (letter). Journal of Clinical Psychiatry, 45, 361.
10. Doyle, G. D., Laher, M., Kelly, J. G., Byrne, M. M., Clarkson, A. and Zussman, B. D. (1988). The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatrica Scandinavica, 80, S89-S90.
11. Epstein, M. (Ed.) (1995). The Kidney in Liver Disease. Hanley and Belfus, Philadelphia.
12. Hale, A. S. (1993). New antidepressants: use in high-risk patients. Journal of Clinical Psychiatry, 54, S61-S70.
13. Joffe, P., Lyby, K., Jørgensen, T. and Hellstrøm, B. (1993). The kinetics of citalopram in renal failure. Journal of the American Society of Nephrology, 4, S251.
14. Lieberman, J. A., Cooper, T. B., Suckow, R. F., Steinberg, H., Borenstein, M., Brenner, R. and Kane, J. M. (1985). Tricyclic antidepressant and metabolite levels in chronic renal failure. Clinical Pharmacology and Therapeutics, 37, 301-307.
15. Lieberman, J. A., Cooper, T. B., Suckow, R. F., Steinberg, H., Borenstein, M. and Brenner, R. (1986). Tricyclic antidepressant drug and metabolite levels in chronic renal failure. Annals of the New York Academy of Sciences, 463, 304-306.
16. de Montigny, C., Haddjeri, N., Mongeau, R. and Blier, P. (1995). The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs, 4, S13-S17.
17. Preskorn, S. H. (1993). Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Journal of Clinical Psychiatry, 54, S14-S34.
18. Preskorn, S. H. and Fast, C. A. (1991). Therapeutic drug monitoring for antidepressants: efficacy, safety and cost-effectiveness. Journal of Clinical Psychiatry, 52(6), 23-30.
19. Sandoz, M., Vandel, S., Vandel, B., Bonin, B., Hory, B., St Hillier, Y. and Volmat, R. (1984). Metabolism of amitriptyline in patients with chronic renal failure. European Journal of Clinical Pharmacology, 26, 227-232.
20. Schoerlin, M.-P., Horber, F. F., Frey, F. J. and Mayersohn, M. (1990). Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. Journal of Clinical Pharmacology, 30, 272-284.
21. Schwenk, M. H., Verga, M. A. and Wagner, J. D. (1995). Hemodialyzability of sertraline. Clinical Nephrology, 44, 121-124.
22. Stoeckel, K., Pfefen, J. P., Mayersohn, M., Schoerlin, M.-P., Anderssen, C., Ohnhaus, E. E., Frey, F. J. and Guentert, T. W. (1990). Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatrica Scandinavica, 82, S94-S97.
23. Tasset, J. J., Singh, S. and Pesce, A. J. (1985). Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Therapeutic Drug Monitoring, 7, 255-257.
24. Timmer, C. J., Lohmann, A. A. M. and Mink, C. P. A. (1995). Pharmacokinetic dose-proportionality at steady state of mirtazapine from Remeron tablets. Human Psychopharmacology, 10, S97-S106.
25. Timmer, C. J., Paanakker, J. E. and Van Hal, H. M. J. (1996). Pharmacokinetics from orally administered tablets: influence of gender, age, and treatment regimen. Human Psychopharmacology, 11, 497-509.
26. Troy, S. M., Schultz, R. W., Parker, V. D., Chiang, S. T. and Blum, R. A. (1994). The effect of renal disease on the disposition of venlafaxine. Clinical Pharmacology and Therapeutics, 56, 14-21.
27. Voortman, G. and Paanakker, J. E. (1995). Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Human Psychopharmacology, 10, S83-S96.
28. Winer, B. J. (1971). Statistical Principles in Experimental Design. McGraw-Hill, New York.
29. Young, R. C. (1991). Hydroxylated metabolites of antidepressants. Psychopharmacology Bulletin, 27, 521-532.